



Rabinovich, Roberto A. and Miller, Bruce E. and Wrobel, Karolina and Ranjit, Kareshma and Williams, Michelle C. and Drost,, Ellen and Edwards, Lisa D. and Lomas, David A. and Rennard, Stephen I. and Agustí, Alvar and Tal-Singer, Ruth and Vestbo, Jørgen and Wouters, Emiel F.M. and John, Michelle and van Beek, Edwin J.R. and Murchison, John T. and Bolton, Charlotte E. and MacNee, William and Huang, Jeffrey T.J. (2016) Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. *European Respiratory Journal*, 47 (5). pp. 1365-1373. ISSN 0903-1936

**Access from the University of Nottingham repository:**

<http://eprints.nottingham.ac.uk/33390/1/Circulating%20desmosine%20in%20COPD22122015.pdf>

**Copyright and reuse:**

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: [http://eprints.nottingham.ac.uk/end\\_user\\_agreement.pdf](http://eprints.nottingham.ac.uk/end_user_agreement.pdf)

**A note on versions:**

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact [eprints@nottingham.ac.uk](mailto:eprints@nottingham.ac.uk)

## **Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD**

**Roberto A. Rabinovich<sup>1</sup>, Bruce E. Miller<sup>2</sup>, Karolina Wrobel<sup>3</sup>, Kareshma Ranjit<sup>1</sup>, Michelle C Williams<sup>4</sup>, Ellen Drost<sup>1</sup>, Lisa D. Edwards<sup>5</sup>, David A. Lomas<sup>6</sup>, Stephen I. Rennard<sup>7</sup>, Alvar Agustí<sup>8</sup>, Ruth Tal-Singer<sup>2</sup>, Jørgen Vestbo<sup>9</sup>, Emiel F.M. Wouters<sup>10</sup>, Michelle John<sup>11</sup>, Edwin J.R. van Beek<sup>12</sup>, John T Murchison<sup>13</sup>, Charlotte E Bolton<sup>11</sup>, William MacNee<sup>1</sup> and Jeffrey T.J. Huang<sup>3</sup>; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.**

- 1- Edinburgh Lung and the Environment Group Initiative (ELEGI), Centre for Inflammation and Research, Queens Medical Research Institute, Edinburgh;
- 2- Respiratory Therapy Area Unit, GSK, King of Prussia, Pennsylvania, USA;
- 3- Medical Research Institute, School of Medicine, University of Dundee, Scotland, UK;
- 4- University/BHF Centre for Cardiovascular Science, Chancellor's Building, SU305, 49 Little France Crescent, Edinburgh EH16SUF, UK;
- 5- PAREXEL International, Research Triangle Park, North Carolina, USA
- 6- Faculty of Medical Sciences, University College London, London, UK;
- 7- Division of Pulmonary, Critical Care, Sleep and Allergy, University of Nebraska, Omaha, NE, USA; Clinical Discovery Unit, AstraZeneca, Cambridge, UK;
- 8- Servei de Pneumologia, Thorax Institute. Hospital Clinic, IDIBAPS, Universitat de Barcelona and CIBER Enfermedades Respiratorias (CIBERES), Spain;
- 9- Centre for Respiratory Medicine and Allergy, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, UK;
- 10- Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands;
- 11- Nottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK;
- 12- Clinical Research Imaging Centre, Queens Medical Research Institute, Edinburgh.
- 13- Department of Radiology, Royal Infirmary of Edinburgh, Scotland, UK.

**Correspondence:** Roberto A. Rabinovich. ELEGI Colt Laboratory, Centre for Inflammation Research. The Queen's Medical Research Institute, University of Edinburgh. 47 Little France Crescent. EDINBURGH, Scotland U.K. EH16 4TJ.

Email: [roberto.rabinovich@ed.ac.uk](mailto:roberto.rabinovich@ed.ac.uk)

### **Authors Contributions:**

Conception and design: RR, WM, JH.

Realisation, analysis and interpretation: RR, WM, JH, KR, MW.

Drafting the manuscript for important intellectual contents: RR, WM, JH, BM, KW, KR, MW, ED, LE, DL, SR, AA, RTS, JV, EW, MJ, ChB, EVB, JM.

**Keywords:** COPD comorbidities and mortality, desmosine and elastin degradation, atherosclerosis, inflammation, biomarker.

**Body Text**

**Word Count:** 3480

This article has an online Supplementary File.

**Take Home:**

Elastin degradation is a hallmark of emphysema and may also have a role in the pathogenesis of atherosclerosis associated with COPD, however, the relationship between the levels of desmosine, a marker of elastin degradation, and emphysema or cardiovascular disease are not fully understood. This study shows that elevated plasma desmosine levels relate to cardiovascular comorbidities, atherosclerotic burden and aortic stiffness and predicts all-cause mortality in COPD, but do not relate to emphysema severity or progression.

## ABSTRACT

Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with COPD. Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality.

pDES was measured in 1,177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest CT scans. Aortic arterial stiffness was measured as the aortic–femoral pulse wave velocity.

pDES was elevated in patients with cardiovascular disease (CVD) ( $p < 0.005$ ) and correlated with age ( $\rho = 0.39$ ,  $p < 0.0005$ ), CACS ( $\rho = 0.19$ ,  $p < 0.0005$ ) mMRC ( $\rho = 0.15$ ,  $p < 0.0005$ ), 6MWD ( $\rho = -0.17$ ,  $p < 0.0005$ ) and BODE index ( $\rho = 0.10$ ,  $p < 0.01$ ), but not with emphysema, emphysema progression or FEV<sub>1</sub> decline. pDES predicted all-cause mortality independently of several confounding factors ( $p < 0.005$ ). In an independent cohort of 186 patients with COPD and 110 control subjects, pDES levels were higher in COPD patients with CVD and correlated with arterial stiffness ( $p < 0.05$ ).

In COPD, excess elastin degradation relates to cardiovascular comorbidities, atherosclerosis, arterial stiffness systemic inflammation and mortality, but not to emphysema or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in COPD.

**Abstract word count**      195 words

## INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterized by persistent progressive airflow limitation, and is associated with an enhanced inflammatory response in the lungs to the inhalation of noxious particles and gases [1]. COPD is also frequently complicated by the development of extra-pulmonary comorbidities that have important implications for morbidity and mortality [2], in particular cardiovascular disease (CVD ) [3, 4].

We have previously proposed that elastin degradation could potentially contribute to both the pulmonary and extra-pulmonary manifestations of COPD [5] and may represent a mechanistic link between emphysema and the increased risk of cardiovascular disease [6]. The destruction of elastin in alveolar walls by proteases as part of chronic tobacco smoking-induced lung inflammation, is a central feature of the pathogenesis of emphysema [7]. Recent studies have shown that arterial stiffness, a biomarker of cardiovascular risk [8], is increased in COPD patients [6, 9, 10]. Increased arterial stiffness may result from increased elastin degradation and a relative increase in collagen in arterial walls, as occurs with aging [11, 12] and atherosclerosis [13]. Indeed we have shown that increased arterial stiffness in COPD is associated with increased elastin degradation in the skin [14] and with emphysema in COPD patients [15].

Thus, elastin degradation could potentially contribute to both the pulmonary and extra-pulmonary manifestations of COPD [5] and may represent a mechanistic link between COPD and the increased risk of cardiovascular disease in this condition [6]. Desmosine, and its isomer iso-desmosine, result from the condensation of four lysine residues in and between elastin proteins after oxidation by lysyl-oxidase and are

released when elastin is degraded. These represent ideal biomarkers to monitor elastin degradation since these special cross-links exist only in mature elastin [16]. The potential of desmosine, usually measured in urine, as a biomarker for pulmonary emphysema has been extensively studied in the last 40 years. However, inconclusive results have hindered its potential utility [16]. With improvements in analytical methods [17-19], we recently demonstrated that plasma total desmosine is elevated in 30-40% of COPD patients [18], results that were confirmed in a larger study [20]. However, the potential of plasma desmosine (pDES) as a biomarker of the severity or progression of emphysema and its role as a marker of cardiovascular comorbidities in COPD remains unclear.

The aim of this study was to explore the relationship of pDES with emphysema, emphysema progression, cardiovascular comorbidities, coronary artery calcium score (CACS), as a surrogate of coronary atherosclerosis, and mortality in a cohort of patients with COPD from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. A second independent cohort was used to extend the findings in the ECLIPSE cohort.

## **METHODS**

### **Study Population and Ethics**

Nine hundred and ninety one stable patients with COPD from the ECLIPSE study [21], and 186 patients with COPD and 110 age, gender and smoking matched controls from a second independent cohort (The Association of Lung Function and Cardiovascular Risk – Nottingham) [22], were studied.

All subjects were > 40 years old of European descent, and had a smoking history of  $\geq 10$  pack years. Patients with COPD in both cohorts were current or ex-smokers ( $\geq 10$  pack years), with baseline post-bronchodilator  $FEV_1 < 80\%$  of predicted and  $FEV_1/FVC < 0.7$  and were studied when clinically stable.

Ethics committees of all participating institutions approved the study and written informed consent was obtained from all subjects.

## **MEASUREMENTS**

### **Circulating inflammatory biomarkers**

In blood samples from the ECLIPSE cohort, inflammatory markers were measured in serum or plasma as previously described [23, 24].

### **Plasma desmosine (pDES) measurements**

Total pDES concentration was measured using a modified assay of a validated isotope dilution LC-MS/MS method [17] at year 1 and 2 in the ECLIPSE cohort and at baseline in the Nottingham cohort.

### **Computed tomography**

In the ECLIPSE study, subjects underwent a low-dose chest CT scan (GE Healthcare or Siemens Healthcare) at baseline, year 1 and 3. All CT scans were analysed at a central laboratory using Pulmonary Workstation 2.0 software (VIDA Diagnostics, Coralville, IA. USA) [25].

Emphysema was measured as the percentage of low attenuation areas < -950 Hounsfield units in the whole lung (%LAA) or the 15<sup>th</sup> percentile of the frequency histogram of lung density values when the progression of emphysema was assessed, as previously described [26]. Emphysema was considered to be present if %LAA was greater than 10 % [25]. The %LAA was also assessed as a continuous variable.

### **Coronary artery calcium score (CACS)**

CACS was assessed on CT lung images in the ECLIPSE cohort with a low spatial frequency algorithm as previously described [27] with images analysed using the Agatston scoring method [28].

### **Arterial stiffness**

Arterial stiffness was measured in the Nottingham cohort as the carotid - femoral pulse wave velocity (aortic pulse wave velocity, PWV) using Vicorder (Skidmore Medical, UK) in triplicate and the average recorded [29].

### **Statistical analysis**

Data are expressed as mean±SD. pDES levels between paired samples was assessed using Wilcoxon test. Comparisons between groups were conducted using



analysis of variance (ANOVA) with Student-Newman-Keuls as a post-hoc test or the Kruskal Wallis equivalent with Dunn's test as a post-hoc test for non-normally distributed variables. Analysis of covariance (ANCOVA) was used to control for potential confounders. Chi square tests were used to compare frequencies. Correlations were calculated as Pearson's correlation coefficient or Spearman's correlation coefficient for non-normally distributed variables. Logistic regression was conducted to describe the effect of several covariates on death as an event (as the dependent variable).

A Cox proportional hazards models was constructed to compare mortality between subject groups. Analyses were conducted using the SAS Version 9.3 (SAS Institute Inc, Cary, NC, USA). Benjamini-Hochberg False Discovery Rate (FDR) method was used to adjust the multiple hypothesis tests.

(See online data supplement for more details on the methods).

## RESULTS

### Investigation of elastin degradation in the ECLIPSE cohort

Of the 2746 subjects enrolled in ECLIPSE, one thousand COPD patients were included in the study. This cohort of patients was selected to cover for the whole spectrum of severity in lung function, lung function decline and emphysema progression (between baseline and year 3). A total of 991 blood samples from year 1 were available for analysis. From these, 813 patients with COPD had CT scans available for analysis after the exclusion of scans with poor image quality [27]. The demographic details of the study population are shown in **Table 1** and a comparison between the patients in the ECLIPSE cohort not included in the study and the present cohort is shown in the online supplement **Table S1**. The two populations were similar in age, gender, body composition, and smoking history. There were statistically significant differences in lung function and 6MWD, however, these differences were very small and considered to be clinically irrelevant.

### ***pDES and patient characteristics***

pDES levels in the ECLIPSE cohort correlated positively and significantly (univariate analysis) with age ( $\rho=0.39$ ,  $p<0.0005$ ), mMRC ( $\rho=0.15$ ,  $p<0.0005$ ), BODE index ( $\rho=0.10$ ,  $p<0.01$ ), hospitalisations ( $\rho=0.08$ ,  $p<0.05$ ), pack/years ( $\rho=0.07$ ,  $p<0.05$ ) and the CACS score ( $\rho=0.19$ ,  $p<0.0005$ ). pDES correlated negatively with FVC ( $\rho=-0.09$ ,  $p<0.05$ ), 6MWD ( $\rho=-0.17$ ,  $p<0.0005$ ) and SpO<sub>2</sub> ( $\rho=-0.1$ ,  $p<0.05$ ). Significant positive correlations were found between pDES levels and inflammatory biomarkers: fibrinogen ( $\rho=0.12$ ,  $p<0.001$ ), IL-6 ( $\rho=0.15$ ,  $p<0.0005$ ), IL-8

( $\rho=0.11$ ,  $p<0.005$ ), CCL-18 ( $\rho=0.13$ ,  $p<0.0005$ ) and SP-D ( $\rho=0.10$ ,  $p<0.01$ ). No difference in pDES levels was observed between genders. **Most of these correlations (except age) are considered weak albeit significant correlations (as a result of large sample size).**

Subjects were divided into quartiles of pDES levels. The highest pDES quartile had significantly higher values for age, mMRC dyspnoea score, number of hospitalisations recorded in the three years of the study, fibrinogen, IL-6, CCL-18, SP-D and lower values of 6MWD (**Table 2S**).

***Changes in pDES in stable COPD over 1 year and characteristics of patient with persistent elastin degradation***

From the 991 patients assessed at year one, 981 samples were available for pDES assessment one year later. The levels at the two visits were significantly correlated ( $r=0.37$ ;  $p<0.0001$ ). There were no significant differences between pDES levels measured at year 1 and 2 ( $p=0.75$ ), and mean differences (bias) between both assessments was 0.0019 ng/mL showing a good stability of pDES in repeated assessments (**Figure 1S, online supplement**). **We have also shown in a previous report a small short term intra-subject variability of pDES over two weeks [18].** This allowed us to use a nominal cut-off pDES of 0.35 ng/mL calculated from the mean + 2.575 x standard deviation (to achieve the 99% confidence level) derived from healthy volunteers in a previous study [18]. We found that  $\approx$ approximately 50% of patients in the ECLIPSE cohort had abnormal elastin degradation at year 1, **which (65%)** continued to have high elastin degradation activity one year later. In the other 50% of patients that had low initial pDES levels, most (63%) continued to have low pDES levels one year later. To investigate potential relationships between persistent

elastin degradation and patient characteristics, patients were divided into four groups according to the nominal cut-off for pDES: pDES<sub>LL</sub> (n=312): with normal levels of pDES at both visits (persistently low), pDES<sub>LH</sub> (n=180): normal levels at year 1 but high levels at year 2, pDES<sub>HL</sub> (n=173): high levels at year 1 and normal levels at year 2; and, pDES<sub>HH</sub> (n=316): with high pDES levels at both time points (persistently high). pDES<sub>HH</sub> patients were older, had lower FEV<sub>1</sub>, SpO<sub>2</sub> and 6MWD and higher mMRC, number of years smoked, BODE index, number of hospitalisations recorded in the first three years of the study, fibrinogen, IL-6, CCL-18 and circulating neutrophils in comparison to pDES<sub>LL</sub> (**Table 2**).

### ***The relationship between pDES and emphysema and FEV<sub>1</sub> severity and progression***

No differences in pDES were seen between patients with and without emphysema on CT scan (p=0.68) and no significant correlations were found between pDES and emphysema (%LAA) (rho=0.07, p=ns), emphysema progression (change in PD15) (rho=0.02, p=ns), FEV<sub>1</sub> (rho=-0.05, p=ns), or FEV<sub>1</sub> decline (rho=-0.01, p=ns). There were no differences in %LAA between the different pDES quartiles (p=0.27) or between pDES<sub>LL</sub> and pDES<sub>HH</sub> patients (Kruskal Wallis p=0.01, Dunn post hoc test: significance only between pDES<sub>LN</sub> and pDES<sub>NL</sub>).

### ***pDES and cardiovascular comorbidity***

A self-reported history of cardiovascular disease (CVD) was present in 25% of patients (**Table 1**). pDES was higher in patients with a history of CVD compared to those without CVD (p<0.005) and specifically in patients with hypertension (p<0.0005), heart attack (p<0.05) and heart failure (p<0.05) (**Figure 2S, online**

**supplement).**

We further investigated the relationship between aortic calcification, a surrogate for atherosclerotic burden, and elastin degradation. CACS was significantly higher in the highest pDES quartile compared with all other quartiles at both year 1 and 2 ( $p < 0.0005$ , **Figure 3S**). After correcting for %LAA, age, gender, cumulative smoking history (pack/year history), years smoked and inflammation, the significance remains for year 2 results but year 1, suggesting the correlation is confounded with these variables. When grouping based on pDES levels at both visits. pDES<sub>HH</sub> patients had a higher Agatston score in comparison with pDES<sub>LL</sub>, pDES<sub>LH</sub> and pDES<sub>HL</sub> patients ( $p < 0.0005$ ) (**Figure 1A**) and remained significant after correcting for the mentioned confounders.

Patients were divided into commonly defined CACS groups [27], low (<100 Agatston units (AU)), intermediate (101–400 AU), high (401– 1000 AU) or very high (>1000 AU) CACS. Patients with very high Agatston score at baseline were more likely to have high pDES levels in the subsequent two years (pDES<sub>HH</sub>) (**Figure 1B**), showing that persistently high pDES levels associate with very high Agatston score.

### ***pDES and mortality***

pDES levels were higher in patients who died during the three years follow-up period ( $p < 0.001$ ) than in those who survived. Patients who died during the three years follow-up period had also higher values for age, fibrinogen, IL-6 and CCL18.

In a logistic regression with death as the dependent variable and pDES, age, gender, smoking history, mMRC, hospitalisations, inflammation, CACS and cardiovascular comorbidities as independent variables, only pDES was significantly associated with mortality ( $p < 0.005$ ). For a 0.1 ng/mL of change in pDES the odds ratio is 1.31

(95%CI: 1.12,1.54). Given the other variables in the model are held constant, the odds of death increased by 31 % for each 0.1 ng/mL increase in pDES. A Cox proportional hazards model for patients with COPD and pDES quartiles adjusted for age, gender, smoking history, mMRC, hospitalisations, inflammation, CACS and cardiovascular comorbidities showed that patients in the highest pDES quartile had a significantly lower probability of survival ( $p<0.05$ ) (**Figure 2**).

Patients with persistently high pDES (pDES<sub>HH</sub>) had a higher risk of dying during the 3 years follow-up than the other pDES groups, however, this difference is likely to be driven by age and smoking history as the significance disappeared when adjusted for age, gender and smoking history.

### **The relationship between pDES and arterial stiffness in the Nottingham cohort**

To further evaluate the relationship between pDES and cardiovascular comorbidities and risk in COPD and to eliminate the potential influence of kidney function on pDES levels, an independent cohort [22] of 186 COPD patients and 110 age-gender- and smoking -matched controls (**Table 1**) was studied. COPD patients in this cohort had a similar gender distribution, BMI, pack/years history and SpO<sub>2</sub> but were slightly older, had a slightly higher FEV<sub>1</sub> and worse mMRC compared with the ECLIPSE cohort. pDES levels were not significantly different between the two COPD cohorts and so was the proportion of patients expressing abnormal levels of pDES (54% [Nottingham] vs 50% [ECLIPSE]).

### ***pDES and PWV***

Patients with COPD in the Nottingham cohort had significantly higher pDES

( $0.38 \pm 0.16$  ng/mL) than controls ( $0.30 \pm 0.15$  ng/mL;  $p < 0.0001$ ) and higher PWV ( $10.3 \pm 2.1$  m/sec) than controls ( $9.6 \pm 1.9$  m/sec;  $p < 0.005$ ).

In COPD patients, pDES correlated positively with age ( $r = 0.38$ ,  $p < 0.0001$ ) and PWV ( $r = 0.15$ ,  $p < 0.05$ ) and negatively with FEV<sub>1</sub> ( $r = -0.19$ ,  $p < 0.01$ ). pDES was also higher in patients with COPD and a history of ischemic heart disease (IHD) ( $0.43 \pm 0.18$  ng/mL) compared to those without IHD ( $0.37 \pm 0.15$  ng/mL;  $p = 0.05$ ).

### ***pDES levels and renal function***

There was no significant correlation between pDES and creatinine levels ( $\rho = 0.09$ ,  $p = \text{ns}$ ) or estimated glomerular filtration rate (eGFR) ( $\rho = -0.14$ ,  $p = \text{ns}$ ) nor any differences in creatinine levels ( $p = 0.59$ ) eGFR ( $p = 0.16$ ) between the different pDES quartiles or between patients with normal and abnormal levels of pDES (creatinine levels  $p = 0.25$ , eGFR  $p = 0.18$ ) or between COPD patients and controls (creatinine levels  $p = 0.89$ , eGFR  $p = 0.65$ ).

## DISCUSSION

In the largest study of its kind to date, we have shown that elevated pDES levels relate to cardiovascular comorbidities, aortic stiffness, and mortality in patients with COPD, but not to emphysema, emphysema progression, as assessed by CT scan, or FEV<sub>1</sub> decline. **The association to coronary artery disease was particularly significant in patients with persistently elevated levels of pDES.** We also confirmed that patients with COPD had higher pDES compared with age- and gender-matched controls.

These observations suggest that pDES is predominantly a reflection of elastin degradation in vascular tissue, potentially caused by aberrant inflammation in vascular tissues, contributing to worse cardiovascular outcomes and mortality. This notion is supported by results in a second independent cohort where pDES was related to cardiovascular comorbidities and aortic PWV as a measure of arterial stiffness, suggesting that increased arterial stiffness may also result from systemic elastin degradation in the arterial walls [14].

In contrast, the lack of association between pDES levels and emphysema progression or lung function decline, as assessed by CT scan, suggests that pDES is not a good biomarker of lung elastin degradation.

Our study contrasts with previous studies that have shown associations between lung function [20] or measurements of emphysema [18, 20] and desmosine levels. These differences may be explained by differences in the patient populations studied and differences in the measurements of emphysema (or its surrogate) between studies. We have used measurement of emphysema on CT scans as a direct assessment of emphysema rather than surrogates such as the diffusing capacity for carbon monoxide. Moreover, we selected our population based on emphysema, lung



function, emphysema progression and lung function decline. This has enabled us to be in the best position to assess the relationship between these parameters and pDES.

We suspect that the relative size of cardiovascular tissues compared to the lung may be one explanation for these results. The average adult lung weighs about 1.3 kg of which 28% is elastin protein [30], compared to 4.9 kg of the cardiovascular system (based on 7% of body weight of a 70 kg adult), of which up to 50% of its dry weight consists of elastin [31]. Therefore, the contribution from the cardiovascular system to circulating desmosine may be greater than the lungs. Sputum desmosine, which is increased in COPD patients [32], may be a more sensitive marker of lung elastin degradation. The lack of relationship between pDES and emphysema, as assessed by CT scan, may also relate to diminished lung elastin content in patients with emphysema who have less lung tissue. In addition, processes that affect lung density other than emphysema could contribute to masking a relationship with desmosine. Finally, another possible source of pDES could be from elastin degradation in the skin since we have already shown evidence of increased elastin degradation in the skin of patients with COPD compared to matched controls [14].

As the products of elastin degradation - elastokines - can actively participate in the progression of atherosclerosis by accelerating LDL oxidation and calcification of the vascular wall [33], it is also possible that the association observed was indirect or a combination of direct and indirect effects.

Vascular elastin degradation has previously been shown to occur in several conditions such as atherosclerosis [33], aortic aneurysms [34], hypertension [35] and chronic kidney disease [36]. However, evidence of the role of pDES as a prognostic

biomarker is scarce and inconsistent. Noticeably, increased elastin degradation as assessed by elastin-derived peptides was associated with increased arterial stiffness and with all-cause mortality in chronic kidney disease [36]. In contrast, the EVA study [37] showed that a decrease in serum elastin peptide levels was associated with risk factors for atherosclerosis-related diseases. Our results in a cohort of COPD patients are consistent with the former. While the discrepancy between these studies is unexplained, we suspect that differences in analytical methods, and the study population are the likely causes. MMP2 and cathepsin-S were implicated as key enzymes for the vascular elastin degradation in chronic kidney [36] and lungs [38] diseases, but have never been investigated in the vascular bed in COPD patients. Interestingly, we have shown increased MMP2 and MMP9 gene expression associated with increased elastin degradation in the skin of patients with COPD [14]. Our results suggest that elevated elastin degradation is persistent in a subgroup of COPD patients (e.g. ~30% in the ECLIPSE cohort). This sub-group appears to be older with worse mMRC, BODE index, 6MWD, SpO<sub>2</sub> and CACS, as well as exhibiting high levels of inflammatory biomarkers. Since pDES levels did not correlate with FEV<sub>1</sub> decline in COPD and excess elastin degradation can occur at an early state of the disease, timely identification of this subgroup of patients may offer an attractive strategy for therapeutic and/or lifestyle intervention to improve clinical outcomes. Our results indicate that pDES is a predictor of all-cause mortality in COPD patients. Several other biochemical biomarkers are also able to predict mortality in COPD patients including fibronectin to C-reactive protein ratio [39] and other inflammatory biomarkers [40]. However, in a logistic regression analysis only pDES was significantly related to death after correcting for several variables including

inflammatory markers. pDES may therefore be a good biomarker to identify COPD patients at-risk of death and cardiovascular comorbidity.

As kidney is the major route for desmosine excretion [41], pDES levels could potentially be affected by renal function. We found no difference in renal function between COPD patients and controls in the Nottingham cohort, nor any significant relationship between renal function and pDES. Thus we believe that our observations are not confounded by differences in renal function.

### **Study limitations**

Our study has some limitations. The two cohorts included in this study do not have the same measurements nor did the second cohort have repeated sampling. Therefore we were not able to validate either the lack of relationship between pDES and emphysema or the relationship between prospective changes in pDES and outcomes, nor the positive correlation with CACS. However, this was not the main reason for the inclusion of this second cohort, which was to determine if there was a relationship between pDES and arterial stiffness. It also allowed us to confirm the finding of the relationship between pDES and CVD, and to exclude potential effect of renal function. The confirmation of an association between pDES and cardiovascular risk assessed in a totally independent cohort and with a different marker of cardiovascular risk is, therefore, a strength of this study. **Unfortunately, due to the low prevalence of cardiovascular disease in the control group in the Nottingham cohort, it was not possible to explore the relationship between pDES and CVD in the healthy subjects.**

### **Conclusions**

Circulating desmosine in patients with COPD. December, 2015

Our study shows that pDES in patients with COPD is a useful marker of cardiovascular risk and all-cause mortality and may reflect a mechanistic link between COPD and increased cardiovascular risk.

### **ACKNOWLEDGMENTS**

We thank the CT analysis staff (T Candido, S Cogswell, H Davis, N Farzaneh, L Holy, N Krowchuk, H Lee, E Phillips, C Storness-Bliss, N Tai, A-T Tran, N Tran, E Wang, and T Yokogawa) for technical assistance with the CT analysis and data management.

S. Hussian, M. Alhaddad, H. Bailey and J. Patel and the NRRU are acknowledged for their help on recruitment, sample processing and management in “The association of lung function and cardiovascular risk” study.

Professor van Beek is supported by the Scottish Imaging Network – a Platform of Scientific Excellence (SINAPSE).

DL is supported by the NIHR BRC at UCLH.

## **FUNDING**

The Clinical Research Imaging Centre is supported by NHS Research Scotland (NRS) through NHS Lothian.

“The association of lung function and cardiovascular risk” study was supported by The University of Nottingham (ECRKT) and the former Nottingham Respiratory Biomedical Research Unit.

The ECLIPSE study (GSK study no. SCO104960, NCT00292552) was funded by GSK.

## REFERENCES

1. Rodriguez-Roisin R, Anzueto A, Bourbeau J, Calverley P. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. [www.goldcopd.com2010](http://www.goldcopd.com2010) [updated 2010].
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Annals of Internal Medicine*. 2005;142(4):233-9.
3. Sidney S, Sorel M, Quesenberry CP, Jr., DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. *Chest*. 2005;128(4):2068-75. Epub 2005/10/21.
4. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax*. 2007;62(5):411-5. Epub 2007/02/22.
5. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. *Eur Respir J*. 2014;44(5):1332-52. Epub 2014/10/18.
6. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, Newby DE, Macnee W. Vascular dysfunction in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2009;180(6):513-20. Epub 2009/06/23.
7. Shapiro SD. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. *Proc Assoc Am Physicians*. 1995;107(3):346-52.
8. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, Boutouyrie P, Cameron J, Chen CH, Cruickshank JK, Hwang SJ, Lakatta EG, Laurent S, Maldonado J, Mitchell GF, Najjar SS, Newman AB, Ohishi M, Pannier B, Pereira T, Vasani RS, Shokawa T, Sutton-Tyrell K, Verbeke F, Wang KL, Webb DJ, Willum Hansen T, Zoungas S, McEniery CM, Cockcroft JR, Wilkinson IB. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. *J Am Coll Cardiol*. 2014;63(7):636-46. Epub 2013/11/19.
9. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2007;175(12):1259-65. Epub 2007/03/17.
10. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA, Anderson D, Breen L, Wilkinson IB, McEniery CM, Donaldson K, Newby DE, Macnee W. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. *Thorax*. 2008;63(4):306-11. Epub 2007/11/21.
11. Gaballa MA, Jacob CT, Raya TE, Liu J, Simon B, Goldman S. Large artery remodeling during aging: biaxial passive and active stiffness. *Hypertension*. 1998;32(3):437-43. Epub 1998/09/18.
12. Fornieri C, Quaglino D, Jr., Mori G. Role of the extracellular matrix in age-related modifications of the rat aorta. Ultrastructural, morphometric, and enzymatic evaluations. *Arterioscler Thromb*. 1992;12(9):1008-16. Epub 1992/09/11.
13. Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. *Atherosclerosis*. 1998;140(2):281-95. Epub 1998/12/23.
14. Maclay JD, McAllister DA, Rabinovich R, Haq I, Maxwell S, Hartland S, Connell M, Murchison JT, van Beek EJ, Gray RD, Mills NL, Macnee W. Systemic elastin degradation in chronic obstructive pulmonary disease. *Thorax*. 2012;67(7):606-12. Epub 2012/03/01.

15. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2007;176(12):1208-14. Epub 2007/09/22.
16. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. *Eur Respir J*. 2008;32(5):1146-57.
17. Albarbarawi O, Barton A, Miller D, McSharry C, Chaudhuri R, Thomson NC, Palmer CN, Devereux G, Huang JT. Characterization and validation of an isotope-dilution LC-MS/MS method for quantification of total desmosine and isodesmosine in plasma and serum. *Bioanalysis*. 2013;5(16):1991-2001. Epub 2013/08/14.
18. Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, Weir CJ, Messow M, Stevens N, McSharry C, Feuerstein G, Mukhopadhyay S, Brady J, Palmer CN, Miller D, Thomson NC. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. *Thorax*. 2012;67(6):502-8. Epub 2012/01/18.
19. Boutin M, Berthelette C, Gervais FG, Scholand MB, Hoidal J, Leppert MF, Bateman KP, Thibault P. High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine. *Anal Chem*. 2009;81(5):1881-7. Epub 2009/01/31.
20. Lindberg CA, Engstrom G, de Verdier MG, Nihlen U, Anderson M, Forsman-Semb K, Svartengren M. Total desmosines in plasma and urine correlate with lung function. *Eur Respir J*. 2012;39(4):839-45.
21. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). *Eur Respir J*. 2008;31(4):869-73. Epub 2008/01/25.
22. John M, McKeever T, Al Haddad M, Hall IP, Sayers I, Cockcroft JR, Bolton CE. Assessments of Cardiovascular Risk in Patients with COPD. *Eur Respir J*. 2015;Submitted.
23. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. *Respir Res*. 2011;12:146. Epub 2011/11/08.
24. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2011;183(9):1187-92. Epub 2011/01/11.
25. Gietema HA, Muller NL, Fauerbach PV, Sharma S, Edwards LD, Camp PG, Coxson HO. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. *Acad Radiol*. 2011;18(6):661-71. Epub 2011/03/12.
26. Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, Fauerbach PN, Lomas DA, Macnee W, Mayer RJ, Miller BE, Muller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EF, Vestbo J. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. *Lancet Respir Med*. 2013;1(2):129-36. Epub 2014/01/17.
27. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, Macnee W. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. *Thorax*. 2014. Epub 2014/01/30.



28. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol.* 1990;15(4):827-32. Epub 1990/03/15.
29. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J.* 2006;27(21):2588-605. Epub 2006/09/27.
30. Starcher BC. Elastin and the lung. *Thorax.* 1986;41(8):577-85.
31. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating MT, Li DY. A critical role for elastin signaling in vascular morphogenesis and disease. *Development.* 2003;130(2):411-23. Epub 2002/12/06.
32. Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2011;879(21):1893-8.
33. Maurice P, Blaise S, Gayral S, Debelle L, Laffargue M, Hornebeck W, Duca L. Elastin fragmentation and atherosclerosis progression: the elastokine concept. *Trends Cardiovasc Med.* 2013;23(6):211-21.
34. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. *Atherosclerosis.* 1987;65(1-2):13-21.
35. Arribas SM, Hinek A, Gonzalez MC. Elastic fibres and vascular structure in hypertension. *Pharmacol Ther.* 2006;111(3):771-91. Epub 2006/02/21.
36. Smith ER, Tomlinson LA, Ford ML, McMahan LP, Rajkumar C, Holt SG. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. *Hypertension.* 2012;59(5):973-8.
37. Bizbiz L, Alperovitch A, Robert L. Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study. *Atherosclerosis.* 1997;131(1):73-8. Epub 1997/05/01.
38. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. *Int J Tuberc Lung Dis.* 2008;12(4):361-7.
39. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, Sin DD. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? *Eur Respir J.* 2008;32(6):1451-7. Epub 2008/09/19.
40. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B. Evaluation of CLIPSEI. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS One.* 2012;7(5):e37483.
41. Starcher B, Peterson B. The kinetics of elastolysis: elastin catabolism during experimentally induced fibrosis. *Exp Lung Res.* 1999;25(5):407-24. Epub 1999/09/14.

TABLE 1. CHARACTERISTICS OF THE STUDY GROUP

	ECLIPSE COPD	NOTTINGHAM COPD	NOTTINGHAM Controls	COPD ECLIPSE Vs COPD NOTTINGHAM p-value	COPD Vs Control NOTTINGHAM p-value
n	991	186	110		
Men	633 (64%)	116 (62%)	67 (61%)	NS	
Hypertension (%)	41	31	27		
Angina (%)	11	18	7		
Heart Attack (%)	10				
Heart Failure (%)	6				
Stroke (%)	4				
Age (Years)	63 ± 7.2	68 ± 7.8	65 ± 9.8	<0.0005	NS
BMI (kg.m <sup>-2</sup> )	26.8 ± 5.8	27.2 ± 5.6	27.7 ± 4.6	NS	NS
Pack/Year	47.4 ± 26.0	44.2 ± 25.7	29.4 ± 18.6	NS	<0.0001
mMRC	2.6 ± 1.0	2.9 ± 1.1	1.4 ± 0.6	<0.01	<0.005
FEV <sub>1</sub> (L)	1.4 ± 0.5	1.5 ± 0.6	2.8 ± 0.7	<0.05	<0.0001
FEV <sub>1</sub> (% pred)	50.5 ± 15.2	57.9 ± 18.5	99.9 ± 13.8	<0.0005	<0.0001
FVC (L)	3.1 ± 0.9	3.1 ± 0.9	3.8 ± 1.0	NS	<0.0001
FVC (% pred)	89.2 ± 19.7	93.8 ± 19.9	109.1 ± 17.3	<0.0005	<0.0001
FEV <sub>1</sub> /FVC	0.46 ± 0.1	0.49 ± 0.13	0.74 ± 0.07	<0.005	<0.0001
SpO <sub>2</sub> (%)	94.7 ± 2.8	94.6 ± 2.4	95.5 ± 8.4	NS	<0.0001
6MWD (m)	384 ± 118.9				
6MWD (%pred)	59.5 ± 18.0				
BODE	2.9 ± 2.0				

*Definition of abbreviations:* COPD = patients with Chronic Obstructive Pulmonary Disease; BMI = Body mass index; Pack/Year: cumulative history of smoking; mMRC = modified medical research council dyspnoea score; FEV<sub>1</sub> = forced expiratory volume in the first second; FVC = forced vital capacity; SpO<sub>2</sub> = oxygen saturation; 6MWD = six minute walking distance; BODE= BODE index. Benjamini Hochberg correction was applied to prevent  $\alpha$ -error accumulation.

TABLE 2S. Desmosine Groups

	pDES <sub>LL</sub>	pDES <sub>LH</sub>	pDES <sub>HL</sub>	pDES <sub>HH</sub>	p-value
n (%)	312 (32%)	180 (18%)	173 (18%)	316 (32%)	NS
Current/former smokers	41/59	36/64	36/64	34/66	
Age (Years)	59.7 ± 7.4	62.4 ± 6.7	63.0 ± 6.6	66.7 ± 5.7*	<0.0005
FEV <sub>1</sub> (L)	1.4 ± 0.5	1.3 ± 0.5	1.3 ± 0.4	1.2 ± 0.4*	<0.05
SpO <sub>2</sub> (%)	95.2 ± 2.7	94.7 ± 3.1	94.5 ± 2.8	94.5 ± 2.6*	<0.005
mMRC	1.4 ± 1.0	1.6 ± 1.0	1.6 ± 1.0	1.8 ± 1.1*	<0.0005
Pack/Year	44.0 ± 24.3	49.6 ± 29.8	48.7 ± 20.9	48.1 ± 27.9	<0.01
Years Smoked	37.7 ± 8.8	39 ± 8.8	39.3 ± 10.1	41.0 ± 10.7*	<0.0005
Hospitalisations	0.55 ± 1.5	0.63 ± 1.3	0.71 ± 1.6	0.79 ± 1.6*	<0.01
6MWD (m)	413.8 ± 120.6	382.5 ± 121.0	386.8 ± 110.5	354.7 ± 115.4*	<0.0005
BODE index	2.5 ± 2.0	3.0 ± 1.9	2.8 ± 2.0	3.2 ± 2.0*	<0.0005
%LAA	14.7 ± 10.9	17.7 ± 11.6	17.0 ± 11.5	17.2 ± 11.7	<0.05
Fibrinogen (mg/dL)	437.7 ± 94.4	463.8 ± 97.9	447.4 ± 93.0	474.7 ± 104.9*	<0.0005
IL-6 (pg/mL)	2.8 ± 11.1	4.2 ± 12.6	4.4 ± 15.5	6.7 ± 41.6*	<0.0005
IL-8 (pg/mL)	14.2 ± 37.8	14.6 ± 33.3	12.4 ± 18.0	14.1 ± 36.5*	<0.005
CCL-18 (pg/mL)	104.7 ± 38.8	111.1 ± 41.0	109.9 ± 44.6	121.1 ± 47.8*	<0.0005
Lymphocytes	2.0 ± 0.7	2.1 ± 0.6	2.1 ± 0.7	1.9 ± 0.6*	<0.0005
Lymphocytes (%)	26.9 ± 7.6	26.5 ± 7.5	27.5 ± 8.2	24.4 ± 7.4*	<0.0005
Neutrophils	5.0 ± 1.7	5.3 ± 2.0	4.9 ± 1.7	5.3 ± 1.9	<0.05
Neutrophils (%)	63.7 ± 8.4	64.0 ± 8.3	63.0 ± 8.6	66.0 ± 8.4*	<0.005
SP-D (pg/mL)	131.7 ± 65.5	139.1 ± 95.3	139.6 ± 69.4	144.7 ± 80.7	NS
CACS	267.9 ± 500.5	470.9 ± 831.3	373.6 ± 577.1	651.7 ± 967.8	<0.0001
Cardiovascular hist.	58 (25.1%)	40 (17.3%)	37 (16.0%)	96 (41.6%)	<0.005
Hypertension (%)	92 (24.2%)	77 (20.3%)	59 (15.5%)	152 (40.0%)	<0.0001
Angina (%)	32 (31.1%)	13 (12.6%)	18 (17.5%)	40 (38.8%)	NS
Heart Attack (%)	21 (22.8%)	14 (15.2%)	16 (17.4%)	41 (44.6%)	<0.05
Heart Failure (%)	11 (21.6%)	7 (13.7%)	13 (25.5%)	20 (39.2%)	NS

*Definition of abbreviations:* pDES<sub>LL</sub>: pDES normal in both assessments (initial and 1 year follow-up); pDES<sub>HH</sub>: pDES high values in both assessments. mMRC = modified medical research council dyspnoea score; Hospitalisations = number of hospitalisations recorded in the first three years of the study; 6MWD = six minute walking distance; BODE= BODE index; %LAA: per cent low attenuation areas ;-950 Hounsfield units; IL-6: Interleukin six; IL-8: Interleukin eight; CCL-18: Chemokine (C-C motif) ligand eighteen; **CACS: coronary artery calcification score**. Comparisons among groups were done using Wilcoxon test and Dunn test as a post-hoc test. Benjamini Hochberg correction was applied to prevent  $\alpha$ -error accumulation. (\* statistical difference between pDES<sub>LL</sub> and pDES<sub>HH</sub>).

## FIGURE LEGENDS

### **Figure 1: Relationship between pDES and CACS.**

**Panel A** shows levels of CACS in the four different pDES groups after correcting for %LAA, age, cumulative smoking history (Pack/years) and years smoked. (\* $p < 0.0005$ ).

**Panel B** shows patient's distribution in the different CACS categories (low, intermediate, high and very high) according to their pDES at year 1 and year 2. pDES<sub>LL</sub> (normal pDES levels at both visits, ■), pDES<sub>LH</sub> (normal levels at year 1 that increase 1 year later, ■), pDES<sub>HL</sub> (high levels at year 1 but returning to normal levels one year later, ■) or pDES<sub>HH</sub> (high levels of pDES at both visits, ■). ( $\text{Chi}^2 p < 0.0001$ ).

### **Figure 2: Survival probability in relationship to pDES.**

Cox proportional hazard model for patients with COPD and pDES quartiles adjusted for age, gender, smoking history, hospitalisations, inflammation and CACS. (\* $p < 0.05$ ). A similar result was observed in an unadjusted Cox model (data not shown).